Skip to main content

Carbidopa Disease Interactions

There are 5 disease interactions with carbidopa.

Major

Carbidopa (applies to carbidopa) glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

Carbidopa-levodopa products are contraindicated in patients with narrow-angle glaucoma.

References (1)
  1. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
Moderate

Carbidopa (applies to carbidopa) depression

Moderate Potential Hazard, Moderate plausibility.

Caution and observation is recommended when treating patients with carbidopa, as depression with concomitant suicidal tendencies may develop or be exacerbated.

References (1)
  1. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
Moderate

Carbidopa/levodopa (applies to carbidopa) sleep disorders

Moderate Potential Hazard, Moderate plausibility.

Patients treated with products containing carbidopa and levodopa report excessive somnolence and falling asleep while engaged in daily activities, sometimes with no warning sign of drowsiness. Advise patients about the risks, especially those suffering from sleep disorders or using concomitant sedating medications.

References (3)
  1. (2024) "Product Information. Vyalev (foscarbidopa-foslevodopa)." AbbVie US LLC
  2. (2022) "Product Information. Inbrija (levodopa)." Acorda Therapeutics, DailyMed
  3. (2018) "Product Information. Carbidopa (carbidopa)." Aurobindo Pharma USA Inc
Moderate

Dopamine agonists (applies to carbidopa) hypotension

Moderate Potential Hazard, Moderate plausibility.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension at any time, but especially during dose escalation. Additionally, patients with Parkinson's disease may have an impaired capacity to respond to an orthostatic challenge. For these reasons, patients with Parkinson's disease (or restless legs syndrome) who are being treated with dopaminergic agonists typically require careful monitoring for signs/symptoms of orthostatic hypotension, especially during dose escalation, and should be advised of this risk.

References (14)
  1. (2022) "Product Information. Inbrija (levodopa)." Acorda Therapeutics, DailyMed
  2. (2025) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC, SUPPL-25
  3. (2025) "Product Information. Onapgo Prefilled Cartridges (apomorphine)." US WorldMeds LLC
  4. (2023) "Product Information. Gocovri (amantadine)." Adamas Pharmaceuticals Inc., DailyMed
  5. (2020) "Product Information. Cycloset (bromocriptine)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  6. (2020) "Product Information. Lodosyn (carbidopa)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  7. (2020) "Product Information. Comtan (entacapone)." Almatica Pharma Inc, DailyMed
  8. (2004) "Product Information. Permax (pergolide)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  9. (2023) "Product Information. Pramipexole Dihydrochloride (pramipexole)." Major Pharmaceuticals Inc, DailyMed
  10. (2020) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, DailyMed
  11. (2024) "Product Information. ROPINIRole Hydrochloride ER (rOPINIRole)." Solco Healthcare US, DailyMed
  12. (2021) "Product Information. Neupro (rotigotine)." UCB Pharma Inc, DailyMed
  13. (2021) "Product Information. Zelapar (selegiline)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  14. (2020) "Product Information. Tasmar (tolcapone)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
Moderate

Dopaminergic antiparkinsonian agents (applies to carbidopa) psychosis

Moderate Potential Hazard, Moderate plausibility.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinsonian agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs. The use of bromocriptine in patients with severe psychotic disorders is not recommended.

References (13)
  1. (2021) "Product Information. Xadago (safinamide)." US WorldMeds LLC, SUPPL-6
  2. (2022) "Product Information. Inbrija (levodopa)." Acorda Therapeutics, DailyMed
  3. (2025) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC, SUPPL-25
  4. (2025) "Product Information. Onapgo Prefilled Cartridges (apomorphine)." US WorldMeds LLC
  5. (2023) "Product Information. Gocovri (amantadine)." Adamas Pharmaceuticals Inc., DailyMed
  6. (2020) "Product Information. Cycloset (bromocriptine)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  7. (2020) "Product Information. Lodosyn (carbidopa)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed
  8. (2020) "Product Information. Comtan (entacapone)." Almatica Pharma Inc, DailyMed
  9. (2023) "Product Information. Pramipexole Dihydrochloride (pramipexole)." Major Pharmaceuticals Inc, DailyMed
  10. (2020) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, DailyMed
  11. (2024) "Product Information. ROPINIRole Hydrochloride ER (rOPINIRole)." Solco Healthcare US, DailyMed
  12. (2021) "Product Information. Neupro (rotigotine)." UCB Pharma Inc, DailyMed
  13. (2020) "Product Information. Tasmar (tolcapone)." Bausch Health US (formerly Valeant Pharmaceuticals), DailyMed

Switch to consumer interaction data

Carbidopa drug interactions

There are 3 drug interactions with carbidopa.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.